Results 51 to 60 of about 12,661 (240)

Association of the T-cell Regulatory Ggene CTLA-4 with Suscep-tibility to Autoimmune Thyroid Disease in Population of Novosibirsk

open access: yesКлиническая и экспериментальная тиреоидология, 2008
Autoimmune thyroid disease (AITD) is caused by an immune response to self-thyroid antigen. The cytotoxic T-lymphocyte antigen-4 (CTLA4) gene, encoding a negative regulator of the T-lymphocyte immune response, had been reported to be associated and/or ...

doaj   +1 more source

Alternative immunomodulatory strategies for xenotransplantation: CD80/CD86-CTLA4 pathway-modified immature dendritic cells promote xenograft survival. [PDF]

open access: yesPLoS ONE, 2013
BACKGROUND: Xenotransplantation is a promising approach to circumventing the current organ shortage. However, T-cell-dependent anti-xenoresponses are a major challenge to successful xenografts.
Min Tian   +5 more
doaj   +1 more source

Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque Inflammation and Progression in Hyperlipidemic Mice

open access: yesCells, 2020
T cell-driven inflammation plays a critical role in the initiation and progression of atherosclerosis. The co-inhibitory protein Cytotoxic T-Lymphocyte Associated protein (CTLA) 4 is an important negative regulator of T cell activation.
K. Poels   +8 more
semanticscholar   +1 more source

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma

open access: yesJournal for ImmunoTherapy of Cancer, 2021
Background In metastatic clear cell renal cell carcinoma (ccRCC), different combination therapies, each including anti-PD-1 immune checkpoint blockade (ICB), are applied as first-line treatment.
N. Klümper   +21 more
semanticscholar   +1 more source

Association of candidate gene polymorphisms for autoimmune thyroid diseases in patients with familial diffuse toxic goiter and autoimmune thyroiditis

open access: yesКлиническая и экспериментальная тиреоидология, 2016
Aim: to study the relation polymorphism of some genes of the immune response with familial autoimmune thyroid disease. Materials and methods. 100 patients from 49 families were examined.
Oksana D. Rymar   +6 more
doaj   +1 more source

Local Depletion of Immune Checkpoint Ligand CTLA4 Expressing Cells in Tumor Beds Enhances Antitumor Host Immunity

open access: yesAdvances in Therapy, 2021
Near‐infrared photoimmunotherapy (NIR‐PIT) is a cancer treatment that utilizes antibody‐photoabsorber (IR700) conjugates to selectively kill target cells by exposing them to NIR light. Cytotoxic T‐lymphocyte antigen 4 (CTLA4) is a major immune checkpoint
R. Okada   +6 more
semanticscholar   +1 more source

Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy

open access: yesOncoImmunology, 2018
Cytokines regulate virtually aspects of innate and adaptive immunity, including the initiation, execution and extinction of tumor-targeting immune responses. Over the past three decades, the possibility of using recombinant cytokines as a means to elicit
Elena García-Martínez   +12 more
doaj   +1 more source

CTLA4 gene polymorphism and autoimmunity

open access: yesImmunological Reviews, 2005
Summary:  CD28 and cytotoxic T‐lymphocyte antigen‐4 (CTLA4) are two receptors that have critical but opposing functions in T‐cell stimulation. CD28 promotes a number of T‐cell activities, whereas in contrast CTLA4 is an essential inhibitor of T‐cell responses.
Gough, S, Walker, L, Sansom, D
openaire   +2 more sources

CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC)

open access: yesCancer Cell International, 2020
Background Cytotoxic T-lymphocyte associated protein 4 (CTLA4) inhibitors have been shown to significantly prolong the overall survival (OS) in a wide range of cancers. However, its application in clear cell renal cell carcinoma (ccRCC) is limited due to
Shiyi Liu   +12 more
doaj   +1 more source

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

open access: yesNature
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune ...
F. Skoulidis   +130 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy